Clinical Trial Update: Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC [Phase 2]

View source ↗

Summary

Phase 2 trial of cemiplimab-rwlc for unresectable locally recurrent and/or metastatic cutaneous squamous cell carcinoma has terminated with results posted in 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Squamous Cell Carcinoma
• Cutaneous Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• cemiplimab-rwlc (cemiplimab)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Cutaneous Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Status: TERMINATED | Results posted: 2022-07-14